Όλο το DSpace

Πλοήγηση ανά Θέμα "American Heart Association Inc."

Αποτελέσματα 1-6 από 6

    • Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19 

      Pan M., Vasbinder A., Anderson E., Catalan T., Shadid H.R., Berlin H., Padalia K., O’hayer P., Meloche C., Azam T.U., Khaleel I., Michaud E., Blakely P., Bitar A., Huang Y., Zhao L., Pop-Busui R., Loosen S.H., Chalkias A., Tacke F., Giamarellos-Bourboulis E.J., Reiser J., Eugen-Olsen J., Hayek S.S. (2021)
      BACKGROUND: Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) is thought to affect COVID-19 through modulating levels of angiotensin-converting enzyme 2, the cell entry receptor ...

    • Atrial high-rate episode duration thresholds and thromboembolic risk: A systematic review and meta-analysis 

      Sagris D., Georgiopoulos G., Pateras K., Perlepe K., Korompoki E., Milionis H., Tsiachris D., Chan C., Lip G.Y.H., Ntaios G. (2021)
      BACKGROUND: Available evidence supports an association between atrial high-rate episode (AHRE) burden and thromboembolic risk, but the necessary extent and duration of AHREs to increase the thromboembolic risk remain to ...

    • Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study 

      Paciaroni M., Agnelli G., Falocci N., Tsivgoulis G., Vadikolias K., Liantinioti C., Chondrogianni M., Bovi P., Carletti M., Cappellari M., Zedde M., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Silvestrelli G., Lanari A., Ciccone A., Putaala J., Tomppo L., Tatlisumak T., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., D'Amore C., Becattini C., Mosconi M.G., Cimini L.A., Soloperto R., Masotti L., Vannucchi V., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Sohn S.-I., Marcheselli S., Mumoli N., De Lodovici M.L., Bono G., Furie K.L., Tadi P., Yaghi S., Toni D., Letteri F., Tassinari T., Kargiotis O., Lotti E.M., Flomin Y., Mancuso M., Maccarrone M., Giannini N., Bandini F., Pezzini A., Poli L., Padovani A., Scoditti U., Denti L., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Gourbali V., Orlandi G., Giuntini M., Chiti A., Giorli E., Gialdini G., Corea F., Ageno W., Bellesini M., Colombo G., Monaco S., Baronello M.M., Karapanayiotides T., Caso V. (2017)
      Background--The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated ...

    • Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation: Time to initiation of oral anticoagulant therapy and outcomes 

      Paciaroni M., Bandini F., Agnelli G., Tsivgoulis G., Yaghi S., Furie K.L., Tadi P., Becattini C., Zedde M., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., D’Amore C., Mosconi M.G., Cimini L.A., Altavilla R., Volpi G., Bovi P., Carletti M., Rigatelli A., Cappellari M., Putaala J., Tomppo L., Tatlisumak T., Marcheselli S., Pezzini A., Poli L., Padovani A., Masotti L., Vannucchi V., Sohn S.-I., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Ntaios G., Athanasakis G., Makaritsis K., Karagkiozi E., Vadikolias K., Liantinioti C., Chondrogianni M., Mumoli N., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Corea F., Ageno W., Bellesini M., Colombo G., Silvestrelli G., Ciccone A., Lanari A., Scoditti U., Denti L., Mancuso M., Maccarrone M., Ulivi L., Orlandi G., Giannini N., Gialdini G., Tassinari T., De Lodovici M.L., Bono G., Rueckert C., Baldi A., D'Anna S., Toni D., Letteri F., Giuntini M., Lotti E.M., Flomin Y., Pieroni A., Kargiotis O., Karapanayiotides T., Monaco S., Baronello M.M., Csiba L., Szabó L., Chiti A., Giorli E., Del Sette M., Imberti D., Zabzuni D., Doronin B., Volodina V., Michel P., Vanacker P., Barlinn K., Pallesen L.-P., Barlinn J., Deleu D., Melikyan G., Ibrahim F., Akhtar N., Gourbali V., Caso V. (2018)
      Background—In patients with acute ischemic stroke and atrial fibrillation, early anticoagulation prevents ischemic recurrence but with the risk of hemorrhagic transformation (HT). The aims of this study were to evaluate ...

    • Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source 

      Ntaios G., Perlepe K., Lambrou D., Sirimarco G., Strambo D., Eskandari A., Karagkiozi E., Vemmou A., Koroboki E., Manios E., Makaritsis K., Vemmos K., Michel P. (2019)
      Background: We aimed to assess the prevalence and degree of overlap of potential embolic sources (PES) in patients with embolic stroke of undetermined source (ESUS). Methods and Results: In a pooled data set derived from ...

    • Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19 

      Luo S., Vasbinder A., Du-Fay-de-lavallaz J.M., Gomez J.M.D., Suboc T., Anderson E., Tekumulla A., Shadid H., Berlin H., Pan M., Azam T.U., Khaleel I., Padalia K., Meloche C., O’hayer P., Catalan T., Blakely P., Launius C., Amadi K.-M., Pop-Busui R., Loosen S.H., Chalkias A., Tacke F., Giamarellos-Bourboulis E.J., Altintas I., Eugen-Olsen J., Williams K.A., Volgman A.S., Reiser J., Hayek S.S., on behalf of the ISIC (International Study of Inflammation in COVID-19) Group (2022)
      BACKGROUND: Venous thromboembolism (VTE) contributes significantly to COVID-19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen ...